Weekly Analysts’ Ratings Updates for Artivion (AORT)

Artivion (NYSE: AORT) recently received a number of ratings updates from brokerages and research firms:

• 11/15/2025 – Artivion was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/7/2025 – Artivion had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $50.00 price target on the stock.
• 11/7/2025 – Artivion had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $51.00. They now have a “buy” rating on the stock.
• 11/7/2025 – Artivion had its price target raised by analysts at Citizens Jmp from $47.00 to $53.00. They now have a “market outperform” rating on the stock.
• 11/7/2025 – Artivion had its price target raised by analysts at Needham & Company LLC from $50.00 to $58.00. They now have a “buy” rating on the stock.
• 10/10/2025 – Artivion had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 10/10/2025 – Artivion had its price target raised by analysts at JMP Securities from $42.00 to $47.00. They now have a “market outperform” rating on the stock.
• 10/8/2025 – Artivion had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/29/2025 – Artivion had its price target raised by analysts at Stifel Nicolaus from $40.00 to $46.00. They now have a “buy” rating on the stock.
• 9/29/2025 – Artivion had its price target raised by analysts at Canaccord Genuity Group Inc. from $41.00 to $50.00. They now have a “buy” rating on the stock.
• 9/27/2025 – Artivion had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling

In other news, CEO James P. Mackin sold 34,210 shares of the company’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $45.86, for a total value of $1,568,870.60. Following the sale, the chief executive officer owned 800,993 shares in the company, valued at $36,733,538.98. This represents a 4.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elizabeth A. Hoff sold 4,200 shares of Artivion stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $45.10, for a total value of $189,420.00. Following the transaction, the director owned 27,189 shares of the company’s stock, valued at approximately $1,226,223.90. This represents a 13.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 157,251 shares of company stock valued at $7,105,389 in the last 90 days. 8.10% of the stock is currently owned by insiders.

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.